Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imagion Biosystems Ltd. ( (AU:IBX) ) has issued an announcement.
Imagion Biosystems reported no revenue from ordinary activities for the year ended 31 December 2025, with its net loss after tax widening 108.5% to $4.31 million compared with the prior year. The company’s net tangible assets per share improved from negative 1.11 cents to negative 0.44 cents, no dividends were declared for either year, and its audited financial statements received an unmodified opinion, indicating clean audit assurance despite ongoing operating losses.
The group reported no changes in control over subsidiaries, no associates or joint ventures, and confirmed that its U.S. subsidiary continues to report under IFRS in line with Australian standards. The 2025 annual report has been released to provide further detail on operations and financial performance, underscoring the company’s continued investment phase and the absence of near‑term shareholder returns through dividends.
The most recent analyst rating on (AU:IBX) stock is a Buy with a A$0.03 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is a medical technology company focused on developing diagnostic imaging solutions through its subsidiary Imagion Biosystems Inc. The group prepares its financial records under IFRS, aligned with Australian Accounting Standards, and is listed in Australia with a focus on advancing its biosystems technologies for clinical and commercial applications.
Average Trading Volume: 2,774,714
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$11.28M
For a thorough assessment of IBX stock, go to TipRanks’ Stock Analysis page.